HC Wainwright Reiterates "Buy" Rating for Capricor Therapeutics (NASDAQ:CAPR)

Key Points

• HC Wainwright has reiterated a "Buy" rating for Capricor Therapeutics (NASDAQ:CAPR) with a target price of $24.00, indicating a potential upside of 265.41% from the stock's previous close.
• Capricor Therapeutics' stock traded at $6.57, up 6.1%, with a market capitalization of approximately $300.29 million and a reported EPS of ($0.57), missing analyst estimates.
• Several analysts have rated the stock as a "Buy," bolstering the consensus target price to $22.25 based on optimistic expectations regarding the company’s lead candidate for treating Duchenne muscular dystrophy.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $24.00 target price on the biotechnology company's stock. HC Wainwright's price objective indicates a potential upside of 265.41% from the stock's previous close.

Several other analysts have also issued reports on the stock. Alliance Global Partners reiterated a "buy" rating on shares of Capricor Therapeutics in a research note on Monday, July 14th. Jones Trading reduced their price target on shares of Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating for the company in a research report on Wednesday, June 25th. Oppenheimer reduced their price target on shares of Capricor Therapeutics from $43.00 to $22.00 and set an "outperform" rating for the company in a research report on Monday, June 23rd. B. Riley started coverage on shares of Capricor Therapeutics in a research report on Thursday, June 26th. They set a "buy" rating and a $21.00 price target for the company. Finally, Piper Sandler restated an "overweight" rating and set a $20.00 price target on shares of Capricor Therapeutics in a research report on Friday, July 11th. One equities research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $22.25.

Capricor Therapeutics Stock Up 6.1%

Capricor Therapeutics stock traded up $0.38 during mid-day trading on Thursday, hitting $6.57. 4,450,668 shares of the stock were exchanged, compared to its average volume of 1,912,377. Capricor Therapeutics has a 12 month low of $5.68 and a 12 month high of $23.40. The firm's fifty day simple moving average is $6.94 and its two-hundred day simple moving average is $9.42. The stock has a market capitalization of $300.29 million, a price-to-earnings ratio of -3.98 and a beta of 0.73.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.09). Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.71%. As a group, analysts forecast that Capricor Therapeutics will post -1.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Krilogy Financial LLC increased its stake in shares of Capricor Therapeutics by 9.6% in the first quarter. Krilogy Financial LLC now owns 22,800 shares of the biotechnology company's stock worth $216,000 after buying an additional 2,000 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Capricor Therapeutics by 2.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 113,650 shares of the biotechnology company's stock worth $1,079,000 after buying an additional 2,314 shares during the period. Deutsche Bank AG increased its stake in shares of Capricor Therapeutics by 10.9% in the first quarter. Deutsche Bank AG now owns 28,699 shares of the biotechnology company's stock worth $272,000 after buying an additional 2,822 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Capricor Therapeutics by 31.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,246 shares of the biotechnology company's stock worth $126,000 after buying an additional 3,162 shares during the period. Finally, Legal & General Group Plc increased its stake in shares of Capricor Therapeutics by 8.4% in the second quarter. Legal & General Group Plc now owns 41,273 shares of the biotechnology company's stock worth $410,000 after buying an additional 3,205 shares during the period. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.